Q2 FY2026 · ended Dec 31, 2025 · Revenue $820,188, -26.2% YoY · Filed May 6, 2026
Inmed Pharmaceuticals Inc. (INM) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$820,188
-26.2% vs year-ago quarter
Net income
$-2.33M
-35.0% vs year-ago quarter
Operating cash flow
$-1.14M
+40.8% vs year-ago quarter
Free cash flow
—
EPS
$-0.42
+4.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
5.49M
+95.9% vs year-ago quarter
Net cash
$4.78M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INM (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1728328
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Sep 30, 2026 |
Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $820,188 | $1.1M |
| Net income | -$2.3M | -$5.8M | -$3.0M | -$2.0M | -$1.7M |
| Diluted EPS | -$0.42 | -$1.24 | -$0.73 | -$0.51 | -$0.44 |
| Operating cash flow | -$1.1M | -$3.0M | -$1.7M | -$2.1M | -$1.9M |
| Total assets | $1.3M | $3.0M | $9.1M | $11.2M | $13.4M |
| Total liabilities | $2.5M | $2.0M | $2.2M | $1.6M | $1.8M |
| Stockholders' equity | -$1.2M | $1.1M | $6.9M | $9.6M | $11.6M |
| Cash and investments | $1.1M | $2.2M | $5.2M | $7.0M | $8.7M |
| Total debt | — | — | $420,147 | $531,949 | $640,243 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Sep 18, 2026 | Sep 16, 2026 |
| 10-K | Annual report | Sep 9, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 22, 2026 | Jul 22, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 10, 2026 | Jul 6, 2026 |
All 512 Inmed Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.